Literature DB >> 6203951

Hyperemic response of intracoronary contrast agents during two-dimensional echographic delineation of regional myocardium.

S Kondo, C Tei, S Meerbaum, E Corday, P M Shah.   

Abstract

Several intracoronary echo contrast agents that provided satisfactory regional myocardial delineation with two-dimensional echocardiography were compared in 15 dogs and their effects on coronary blood flow were examined. Reproducible delineation of myocardium subserved from the intracoronary echo contrast injection site was achieved with hand-agitated agents containing greater than or equal to 30% Renografin, greater than or equal to 30% glucose, greater than or equal to 30% sucrose or 6% dextran. After a 2 cc injection of the echo contrast agent, peak hyperemic augmentation of coronary flow was 56.7 +/- 54.4% for 6% dextran, 116.0 +/- 71.1% for 30% Renografin, 119.3 +/- 47.8% for 30% sucrose, 173.8 +/- 38.3% for 30% glucose. Although, 6% dextran resulted in the lowest and shortest hyperemic response of the four agents, computer-derived echo contrast appearance-disappearance analysis indicated a prolonged myocardial contrast decay half-life (21.0 seconds). On the other hand, 30% Renografin had a more rapid myocardial echo contrast washout (T 1/2 = 15.5 seconds), but a significantly greater hyperemic effect was observed. It is concluded that development of echo contrast agents for myocardial contrast two-dimensional echocardiographic assessment of myocardial perfusion will require consideration of alterations in coronary flow due to contrast-induced hyperemia.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6203951     DOI: 10.1016/s0735-1097(84)80333-2

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  1 in total

1.  Contrast echocardiography of the left ventricle an independent predictor of pulmonary artery pressure?

Authors:  R J Zotz; S Genth; R Erbel; H A Dieterich; J Meyer
Journal:  Int J Card Imaging       Date:  1994-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.